Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibromyalgia in cancer patients: a systematic review and clinical implications for integrated care.

Frontiers in pain research (Lausanne, Switzerland)·2026
Same author

Type 1 Diabetes and Multiple Sclerosis Share General Autoimmunity Genetic Variation.

Genes·2026
Same author

Feasibility Assessment of Telehealth-Based Cancer Pain Management Through Machine Learning: A Prospective Clinical Study.

Pain research & management·2026
Same author

Clinical Characteristics at the Diagnosis of New Primary Melanoma in Italy: A Multicenter Retrospective Study Before and After the COVID-19 Pandemic.

Journal of clinical medicine·2026
Same author

Correction: Adopting machine learning to predict breast cancer patients adherence with lifestyle recommendations and quality of life outcomes.

Frontiers in digital health·2026
Same author

Physical Activity, Nutritional Status, and Health-Related Quality of Life in Newly Diagnosed Cancer Patients: Evidence from the NUTRISCREEN Project.

Nutrients·2026

Related Experiment Video

Updated: May 11, 2026

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
07:51

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

Sentinel node biopsy in thin and thick melanoma.

Nicola Mozzillo1, Elisabetta Pennacchioli, Sara Gandini

  • 1Istituto Nazionale per lo Studio e la cura dei tumori Fondazione G.Pascale IRCCS, Naples, Italy. n.mozzillo@isitutotumori.na.it

Annals of Surgical Oncology
|May 31, 2013
PubMed
Summary

Sentinel lymph node biopsy (SNB) is debated for thin and thick melanomas. SNB is useful for staging and treatment decisions in melanoma patients, with mitotic rate predicting positivity.

More Related Videos

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Related Experiment Videos

Last Updated: May 11, 2026

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
07:51

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Area of Science:

  • Oncology
  • Surgical Pathology
  • Dermatology

Background:

  • Sentinel lymph node biopsy (SNB) is standard for melanoma but debated for thin (≤1 mm) and thick (≥4 mm) tumors.
  • Accurate staging is crucial for melanoma treatment and prognosis.

Purpose of the Study:

  • To evaluate the utility of SNB in patients with thin and thick melanomas.
  • To identify clinicopathologic factors associated with sentinel lymph node positivity.
  • To assess the impact of SNB status on overall survival (OS).

Main Methods:

  • Retrospective analysis of 492 thin and 298 thick melanoma patients undergoing SNB (1998-2011).
  • Analysis of associations between clinicopathologic features, sentinel lymph node status, and OS.
  • Statistical analysis to determine significant predictors of outcomes.

Main Results:

  • In thin melanomas, 4.9% had positive SNB; mitotic rate was the sole significant predictor (p=0.0001).
  • Five-year OS was 81% for positive SNB vs. 93% for negative SNB in thin melanomas (p=0.001).
  • In thick melanomas, 39% had positive SNB; 93% of these had high mitotic rates. Five-year OS was 49% vs. 56% (p=0.005).

Conclusions:

  • SNB positivity rate in thin melanoma is 4.9%, with mitotic rate as the key predictor.
  • SNB should be considered for thin melanomas due to its prognostic importance.
  • SNB is recommended for melanomas ≥4 mm for staging and guiding therapy.